Research programme: thymopentin - mondoBIOTECH

Drug Profile

Research programme: thymopentin - mondoBIOTECH

Alternative Names: DasKloster 0112-01; DK-0112; TP 5 - Mondobiotech; TP-5

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator mondoBIOTECH
  • Class Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis
  • Available For Licensing Yes - Sarcoidosis

Highest Development Phases

  • No development reported Sarcoidosis
  • Discontinued Lung disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Sarcoidosis in Switzerland
  • 09 Mar 2011 Research programme: thymopentin - mondoBIOTECH is available for licensing as of 09 Mar 2011.
  • 04 Feb 2011 Research programme: thymopentin - mondoBIOTECH receives Orphan Drug status for Sarcoidosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top